Brooks Labs Approves Scheme of Arrangement for Demerger

Brooks Laboratories Limited's Board of Directors has approved a Scheme of Arrangement for the demerger of its Manufacturing Business into its wholly-owned subsidiary, Abridge Speciality Limited. The demerged undertaking, comprising the manufacturing operations at Baddi, associated sales, exports, and contract manufacturing, represented approximately 96.66% of the company's total turnover in FY26, amounting to ₹8,287.26 lakhs. The rationale includes focused management, operational clarity, and realignment of management and ownership. The scheme is subject to regulatory and shareholder approvals. Post-demerger, the Resulting Company will be renamed Brooks Laboratories Limited, and the Demerged Company will become Xuri Lifesciences Limited.